| PRECLINICAL | evidence | From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease. | Semaglutide | — | 2026-06-26 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis. | Semaglutide | — | 2026-06-26 |
| PRECLINICAL | evidence | Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. | Semaglutide | — | 2026-06-25 |
| PRECLINICAL | evidence | Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence. | Semaglutide | — | 2026-06-25 |
| PRECLINICAL | evidence | Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States. | Semaglutide | — | 2026-06-25 |
| PRECLINICAL | evidence | The risk of retinal vascular events in patients using semaglutide: a scoping review. | Semaglutide | — | 2026-06-25 |
| PRECLINICAL | evidence | A two-timepoint framework for sensitive and specific single-cell activity screening. | Semaglutide | — | 2026-06-25 |
| PRECLINICAL | evidence | Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide? | Semaglutide | — | 2026-06-25 |
| PRECLINICAL | evidence | Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF. | Semaglutide | — | 2026-06-24 |
| PRECLINICAL | evidence | Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology. | Semaglutide | — | 2026-06-24 |
| PRECLINICAL | evidence | Peripheral neuropathic symptoms with GLP-1 receptor agonists: Insights from a large real-world cohort. | Semaglutide | — | 2026-06-24 |
| PRECLINICAL | evidence | Response to Cestari et al. | Semaglutide | — | 2026-06-24 |
| PRECLINICAL | evidence | Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation. | Semaglutide | — | 2026-06-23 |
| PRECLINICAL | evidence | Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism. | Semaglutide | — | 2026-06-23 |
| PRECLINICAL | evidence | The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies. | Semaglutide | — | 2026-06-23 |
| PRECLINICAL | evidence | Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-06-23 |
| PRECLINICAL | evidence | Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. | Semaglutide | — | 2026-06-23 |
| PRECLINICAL | evidence | GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies. | Semaglutide | — | 2026-06-23 |
| PRECLINICAL | evidence | Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis. | Semaglutide | — | 2026-06-22 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: Insights from a Pilot Implementation Program. | Semaglutide | — | 2026-06-22 |
| PRECLINICAL | evidence | Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. | Semaglutide | — | 2026-06-22 |
| PRECLINICAL | evidence | Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review. | Semaglutide | Liver health | 2026-06-22 |
| PRECLINICAL | evidence | Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction. | Semaglutide | — | 2026-06-22 |
| PRECLINICAL | evidence | Current trends in semaglutide therapy and strategies to improve its bioavailability. | Semaglutide | — | 2026-06-21 |
| PRECLINICAL | evidence | Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024. | Semaglutide | — | 2026-06-21 |
| PRECLINICAL | evidence | Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. | Semaglutide | — | 2026-06-20 |
| PRECLINICAL | evidence | Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence. | Semaglutide | — | 2026-06-19 |
| PRECLINICAL | evidence | Eating Disorder Screen Results and GLP-1 Awareness, Interest, and Use in a Nationally Representative Sample of Adults in U.S. Households. | Ozempic | — | 2026-06-19 |
| PRECLINICAL | evidence | Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis. | Semaglutide | — | 2026-06-19 |
| PRECLINICAL | evidence | Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals. | Semaglutide | — | 2026-06-19 |
| PRECLINICAL | evidence | Long-term effects of weight-reducing drugs in people with hypertension. | Semaglutide | — | 2026-06-19 |
| PRECLINICAL | evidence | Efficacy of Initiation of Semaglutide versus SGLT2 inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study. | Semaglutide | — | 2026-06-19 |
| PRECLINICAL | evidence | Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). | Semaglutide | — | 2026-06-19 |
| PRECLINICAL | evidence | Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning. | Semaglutide | — | 2026-06-18 |
| PRECLINICAL | evidence | Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics. | Semaglutide | — | 2026-06-18 |
| PRECLINICAL | evidence | Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis. | Semaglutide | — | 2026-06-18 |
| PRECLINICAL | evidence | ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations. | Semaglutide | — | 2026-06-17 |
| PRECLINICAL | evidence | IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy. | Semaglutide | Glycemic control | 2026-06-17 |
| PRECLINICAL | evidence | Selecting Pharmacologic Interventions for MASH. | Semaglutide | — | 2026-06-17 |
| PRECLINICAL | evidence | Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation. | Semaglutide | — | 2026-06-17 |
| PRECLINICAL | evidence | A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing. | Semaglutide | — | 2026-06-17 |
| PRECLINICAL | evidence | Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | Semaglutide | — | 2026-06-17 |
| PRECLINICAL | evidence | Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study. | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model. | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026). | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians. | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis. | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | Association between Glucagon-like Peptide-1 Receptor Agonist Use and Nonarteritic Anterior Ischemic Optic Neuropathy with Optic Disc Drusen. | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database. | Semaglutide | — | 2026-06-16 |